MX393240B - Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. - Google Patents
Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.Info
- Publication number
- MX393240B MX393240B MX2019002193A MX2019002193A MX393240B MX 393240 B MX393240 B MX 393240B MX 2019002193 A MX2019002193 A MX 2019002193A MX 2019002193 A MX2019002193 A MX 2019002193A MX 393240 B MX393240 B MX 393240B
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolyl
- disubsubstituted
- formula
- steroid
- disubstituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/048267 WO2018039378A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002193A MX2019002193A (es) | 2019-10-07 |
| MX393240B true MX393240B (es) | 2025-03-24 |
Family
ID=59772778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002193A MX393240B (es) | 2016-08-23 | 2017-08-23 | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. |
| MX2022007432A MX2022007432A (es) | 2016-08-23 | 2019-02-22 | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007432A MX2022007432A (es) | 2016-08-23 | 2019-02-22 | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (enExample) |
| EP (2) | EP3504189A1 (enExample) |
| JP (3) | JP2019524853A (enExample) |
| KR (2) | KR20230079470A (enExample) |
| CN (4) | CN115974955A (enExample) |
| AR (3) | AR109393A1 (enExample) |
| AU (3) | AU2017315682B2 (enExample) |
| BR (1) | BR112019003637A2 (enExample) |
| CA (1) | CA3034262A1 (enExample) |
| CL (2) | CL2019000477A1 (enExample) |
| CO (1) | CO2019002596A2 (enExample) |
| EA (1) | EA201990565A1 (enExample) |
| EC (1) | ECSP19020141A (enExample) |
| IL (2) | IL315950A (enExample) |
| JO (1) | JOP20190022B1 (enExample) |
| MA (1) | MA46042A (enExample) |
| MX (2) | MX393240B (enExample) |
| MY (1) | MY200479A (enExample) |
| NZ (1) | NZ791594A (enExample) |
| PE (2) | PE20190915A1 (enExample) |
| PH (1) | PH12019500375A1 (enExample) |
| SG (1) | SG11201901445TA (enExample) |
| TW (2) | TWI808945B (enExample) |
| WO (1) | WO2018039378A1 (enExample) |
| ZA (1) | ZA201901051B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014528485A (ja) | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| IL294306B2 (en) | 2012-08-21 | 2024-01-01 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| RS58297B1 (sr) | 2013-04-17 | 2019-03-29 | Sage Therapeutics Inc | 19-nor c3,3-disupstituisani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| AU2014256228C1 (en) | 2013-04-17 | 2017-09-14 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| BR112016000975B1 (pt) | 2013-07-19 | 2020-10-06 | Sage Therapeutics, Inc. | Compostos esteróides neuroativos e composições compreendendo os mesmos |
| RS61370B1 (sr) | 2013-08-23 | 2021-02-26 | Sage Therapeutics Inc | Neuroaktivni steroidi, njihove kompozicije i upotreba |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| DK3206493T3 (da) | 2014-10-16 | 2020-08-10 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| CN118344424A (zh) | 2014-10-16 | 2024-07-16 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| AU2017297375B2 (en) | 2016-07-11 | 2022-09-15 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| MA46042A (fr) | 2016-08-23 | 2019-07-03 | Sage Therapeutics Inc | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
| AU2018327357B2 (en) * | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| JP2020534270A (ja) * | 2017-09-14 | 2020-11-26 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| EP4484440A3 (en) | 2017-12-08 | 2025-03-26 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| JP2021527092A (ja) * | 2018-06-12 | 2021-10-11 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| IL312610A (en) | 2018-12-05 | 2024-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN111454318A (zh) | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| WO2020155057A1 (zh) * | 2019-01-31 | 2020-08-06 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| US20220220149A1 (en) | 2019-05-28 | 2022-07-14 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| KR102890254B1 (ko) * | 2019-08-07 | 2025-11-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20230414636A1 (en) | 2020-03-25 | 2023-12-28 | Sage Therapeutics, Inc. | Use of gabaa modulators for treatment of respiratory conditions |
| CN116367827A (zh) * | 2020-07-20 | 2023-06-30 | 萨奇治疗股份有限公司 | 19-去甲-c3,3-二取代-c21-n-吡唑基类固醇的制剂及其使用方法 |
| US20230372365A1 (en) * | 2020-10-01 | 2023-11-23 | Andrew D. Levin | Methods of treating fibromyalgia with neuroactive steroids |
| KR20230136599A (ko) | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| KR20230158033A (ko) | 2021-03-17 | 2023-11-17 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| CN117580580A (zh) | 2021-04-29 | 2024-02-20 | 萨奇治疗股份有限公司 | 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇 |
| TW202308654A (zh) | 2021-04-29 | 2023-03-01 | 美商賽吉醫療公司 | 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 |
| BR112024001518A2 (pt) | 2021-07-28 | 2024-04-30 | Sage Therapeutics Inc | Formas cristalinas de um esteroide neuroativo |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| NZ519984A (en) * | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| PL215006B1 (pl) | 2002-02-08 | 2013-10-31 | Ono Pharmaceutical Co | Krystaliczna postac pochodnej piperydyny oraz jej zastosowanie |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| JP2014528485A (ja) | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| BR112014018110B1 (pt) | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL294306B2 (en) | 2012-08-21 | 2024-01-01 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US20150313915A1 (en) | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| AU2014256228C1 (en) | 2013-04-17 | 2017-09-14 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| RS58297B1 (sr) | 2013-04-17 | 2019-03-29 | Sage Therapeutics Inc | 19-nor c3,3-disupstituisani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| BR112016000975B1 (pt) | 2013-07-19 | 2020-10-06 | Sage Therapeutics, Inc. | Compostos esteróides neuroativos e composições compreendendo os mesmos |
| RS61370B1 (sr) | 2013-08-23 | 2021-02-26 | Sage Therapeutics Inc | Neuroaktivni steroidi, njihove kompozicije i upotreba |
| TW201625661A (zh) | 2014-05-29 | 2016-07-16 | 賽吉醫療公司 | 神經活性類固醇，其組合物及其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| DK3206493T3 (da) * | 2014-10-16 | 2020-08-10 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| CN118344424A (zh) | 2014-10-16 | 2024-07-16 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| EP3280420B1 (en) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CA2998134A1 (en) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| US20200306265A1 (en) | 2016-03-08 | 2020-10-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| AU2017297375B2 (en) | 2016-07-11 | 2022-09-15 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| MA46042A (fr) | 2016-08-23 | 2019-07-03 | Sage Therapeutics Inc | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| CN111065394B (zh) | 2017-08-31 | 2023-03-31 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
| AU2018327357B2 (en) | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JP2020534270A (ja) | 2017-09-14 | 2020-11-26 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| KR20200085837A (ko) | 2017-11-10 | 2020-07-15 | 마리누스 파마슈티컬스 인코포레이티드 | 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도 |
| EP4484440A3 (en) | 2017-12-08 | 2025-03-26 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CA3086299A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AU2018392093B2 (en) | 2017-12-22 | 2024-02-01 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| JP2021527092A (ja) | 2018-06-12 | 2021-10-11 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| DK3864022T3 (da) | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
| CA3116892A1 (en) | 2018-10-19 | 2020-04-23 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| IL312610A (en) | 2018-12-05 | 2024-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| KR20220038680A (ko) | 2019-06-27 | 2022-03-29 | 세이지 테라퓨틱스, 인크. | Cns 장애를 치료하기 위한 조성물 및 방법 |
| CA3144701A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| EP4069250A1 (en) | 2019-12-05 | 2022-10-12 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| EP4121438A2 (en) | 2020-03-18 | 2023-01-25 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20230414636A1 (en) | 2020-03-25 | 2023-12-28 | Sage Therapeutics, Inc. | Use of gabaa modulators for treatment of respiratory conditions |
| WO2021262836A1 (en) | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| CN116367827A (zh) | 2020-07-20 | 2023-06-30 | 萨奇治疗股份有限公司 | 19-去甲-c3,3-二取代-c21-n-吡唑基类固醇的制剂及其使用方法 |
| WO2022115381A1 (en) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
| KR20230136599A (ko) | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| KR20230158033A (ko) | 2021-03-17 | 2023-11-17 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| JP2024513581A (ja) | 2021-04-12 | 2024-03-26 | セージ セラピューティクス， インコーポレイテッド | 本態性振戦の治療 |
| CN117580580A (zh) | 2021-04-29 | 2024-02-20 | 萨奇治疗股份有限公司 | 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇 |
| TW202308654A (zh) | 2021-04-29 | 2023-03-01 | 美商賽吉醫療公司 | 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
-
2017
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 IL IL315950A patent/IL315950A/en unknown
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en not_active Ceased
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 NZ NZ791594A patent/NZ791594A/en unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja active Pending
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019002596A2 (es) | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino | |
| CL2018003527A1 (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
| MX2018014154A (es) | Polinucleotidos moduladores. | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| MX2018015280A (es) | Conjugados de anticuerpo y farmaco anti-egfr. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2017001553A (es) | Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
| CO2019011980A2 (es) | Formas cristalinas de (s)-afoxolaner | |
| UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
| BR112017004000A2 (pt) | formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida | |
| PH12020550537A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| CY1125355T1 (el) | Πεντακυκλικη ενωση | |
| BR112017002090A2 (pt) | formulação de fator viii | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| EA202090732A1 (ru) | Составы для трансдермального введения | |
| MX381489B (es) | Compuesto biciclico y uso del mismo para la inhibicion de suv39h2. | |
| MX381590B (es) | Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. | |
| MX2020008488A (es) | Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo. | |
| MX379649B (es) | Derivados de azetidina para formacion de imágenes de tau. | |
| UA120519U (uk) | Використання похідних 4-амінобутанової кислоти як антиамнестичних засобів | |
| UA114469U (xx) | ЗАСТОСУВАННЯ ПРЕПАРАТУ КАПІКОРУ (МЕЛЬДОНІЮ ДИГІДРАТУ І γ -БУТИРОБЕТАЇНУ ДИГІДРАТУ) ЯК НЕФРОПРОТЕКТОРНОГО ЗАСОБУ |